Laboratory of Chemistry, FDA-CDER, 8800 Rockville Pike, Bethesda, MD 20892, USA.
Bioorg Med Chem. 2013 Oct 15;21(20):6224-32. doi: 10.1016/j.bmc.2013.04.071. Epub 2013 May 7.
The bioactivity of a CpG-containing phosphorothioate DNA oligonucleotide with thermolytic 2-(N-formyl-N-methylamino)ethyl (fma) thiophosphate groups in mice led us to investigate the parameters affecting the internalization of these thermosensitive DNA prodrugs in various cell lines. Flow cytometry and confocal microscopy analyses indicate that 5'-fluoresceinated fma-phosphorothioate DNA sequences are poorly internalized in Vero, HeLa and GC-2 cells. However, when four fma-thiophosphate groups of a 15-nucleotide long oligothymidylate prodrug are replaced with 3-(N,N-dimethylamino)prop-1-yl thiophosphate functions, internalization of the positively charged prodrug, under physiological conditions, increased fourfold in HeLa and 40-fold in Vero or GC-2 cells. No cytotoxic effects are observed in Vero cells even at an extracellular prodrug concentration of 50 μM over a period of 72 h. Confocal microscopy studies show that internalization of the positively charged oligothymidylate prodrug in Vero cells is time-dependent with early trafficking of the DNA sequence through endosomal vesicles and, eventually, to the nucleus of the cells. Thus, the incorporation of four 3-(N,N-dimethylamino)prop-1-yl thiophosphate groups into thermosentive fma-phosphorothioate DNA prodrugs is an attractive strategy for efficient cellular internalization of these nucleic acid-based drugs for potential therapeutic indications.
在小鼠体内,含 CpG 的硫代磷酸酯 DNA 寡核苷酸的生物活性导致我们研究了影响这些热敏 DNA 前药在各种细胞系中内化的参数。流式细胞术和共聚焦显微镜分析表明,5'-荧光素化的 fma-硫代磷酸酯 DNA 序列在 Vero、HeLa 和 GC-2 细胞中内化不良。然而,当 15 个核苷酸长的寡胸苷酸前药的四个 fma-硫代磷酸酯基团被 3-(N,N-二甲基氨基)丙-1-基硫代磷酸酯基团取代时,在生理条件下,带正电荷的前药在 HeLa 细胞中的内化增加了四倍,在 Vero 或 GC-2 细胞中增加了 40 倍。即使在 72 小时内,细胞外前药浓度达到 50 μM,Vero 细胞也没有观察到细胞毒性作用。共聚焦显微镜研究表明,带正电荷的寡胸苷酸前药在 Vero 细胞中的内化是时间依赖性的,DNA 序列通过内体小泡早期转运,并最终转运到细胞的细胞核中。因此,将四个 3-(N,N-二甲基氨基)丙-1-基硫代磷酸酯基团掺入热敏 fma-硫代磷酸酯 DNA 前药中是一种有吸引力的策略,可以有效将这些基于核酸的药物内化到细胞中,用于潜在的治疗用途。